Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan

BACKGROUND: A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials aimed at assessing the vaccine's safety, immunogenicity, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakarya, Kunsulu, Kutumbetov, Lespek, Orynbayev, Mukhit, Abduraimov, Yergali, Sultankulova, Kulyaisan, Kassenov, Markhabat, Sarsenbayeva, Gulbanu, Kulmagambetov, Ilyas, Davlyatshin, Timur, Sergeeva, Maria, Stukova, Marina, Khairullin, Berik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363482/
https://www.ncbi.nlm.nih.gov/pubmed/34414368
http://dx.doi.org/10.1016/j.eclinm.2021.101078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363482/
https://www.ncbi.nlm.nih.gov/pubmed/34414368
http://dx.doi.org/10.1016/j.eclinm.2021.101078

Ejemplares similares